3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Colorectal Neoplasms
476
Carcinoma, Hepatocellular
131
Rectal Neoplasms
114
Colonic Neoplasms
110
Neoplasm Metastasis
62
Pancreatic Neoplasms
54
Liver Neoplasms
44
Stomach Neoplasms
37
Neoplasms
37
Esophageal Neoplasms
21
Carcinoma, Non-Small-Cell Lung
21
Colorectal Cancer Metastatic
19
Ovarian Neoplasms
15
Gastrointestinal Neoplasms
14
Breast Neoplasms
13
Biliary Tract Neoplasms
13
Adenocarcinoma
11
Lung Neoplasms
10
Carcinoma, Renal Cell
10
Digestive System Neoplasms
9
Cholangiocarcinoma
9
Intestinal Neoplasms
8
Melanoma
7
Gallbladder Neoplasms
7
Glioblastoma
6
Endometrial Neoplasms
6
Uterine Cervical Neoplasms
5
Triple Negative Breast Neoplasms
5
Sarcoma
5
Prostatic Neoplasms
5
Interventions
Sorafenib
5
lenvatinib
3
sintilimab
2
pembrolizumab
2
halofantrine
2
camrelizumab
2
atezolizumab
2
Immunotherapy
2
Blood Specimen Collection
2
Bevacizumab
2
Antibodies
2
trifluridine tipiracil drug combination
1
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
linifanib
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
durvalumab
1
bavituximab
1
avelumab
1
User-Centered Design
1
Sunitinib
1
Sufentanil
1
Standard of Care
1
Shadowing Technique, Histology
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Liver Diseases
×
Bevacizumab
×
Gastrointestinal
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled